Propanc Biopharma, Inc. (PPCB) stock
PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$1.94+0.02 (+1.09%)
Close on Nov 13, 2026Market cap $12.29MP/E –Yield –
Propanc Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Propanc Biopharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.02M, up 360.4% year over year. For fiscal 2026 it was $625.48K, up 179.6% from the year before. Over ten years it grew -8.0% a year on average. The highest annual figure on record is $1.83M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $625.48K | +179.6% |
| FY2025 | Jun 30, 2025 | $223.72K | -9.8% |
| FY2024 | Jun 30, 2024 | $248.10K | +0.1% |
| FY2023 | Jun 30, 2023 | $247.92K | -3.2% |
| FY2022 | Jun 30, 2022 | $256.05K | +10.9% |
| FY2021 | Jun 30, 2021 | $230.96K | +28.3% |
| FY2020 | Jun 30, 2020 | $179.99K | -30.9% |
| FY2019 | Jun 30, 2019 | $260.34K | -85.7% |
| FY2018 | Jun 30, 2018 | $1.83M | +87.9% |
| FY2017 | Jun 30, 2017 | $971.77K | -32.8% |
| FY2016 | Jun 30, 2016 | $1.45M | +977.2% |
| FY2015 | Jun 30, 2015 | $134.32K | +1544.5% |
| FY2014 | Jun 30, 2014 | $8.17K | -33.8% |
| FY2013 | Jun 30, 2013 | $12.34K | +133.8% |
| FY2012 | Jun 30, 2012 | $5.28K | -98.6% |
| FY2011 | Jun 30, 2011 | $385.78K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $457.68K | +660.2% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $375.66K | +601.9% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $169.66K | +213.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $19.96K | -63.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $60.20K | -2.5% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $53.52K | +2.2% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $54.10K | -17.3% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $54.39K | -52.3% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $61.71K | +280.0% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $52.39K | +819.8% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $65.45K | -0.9% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $114.02K | +52.3% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $16.24K | -84.0% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $5.70K | -94.7% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $66.02K | +31.0% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $74.88K | +47.5% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $101.33K | +117.7% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $108.35K | +27.4% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $50.40K | +12.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $50.75K | +1.2% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $46.55K | -8.4% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $85.06K | +49.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $44.89K | -21.9% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $50.17K | +135481.1% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $50.85K | -22.2% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $57.09K | +0.7% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $57.48K | +9.2% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $37 | -100.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $65.37K | +16.3% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $56.71K | -62.7% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $52.66K | -29.9% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $94.78K | -90.8% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $56.19K | -90.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $152.12K | -40.8% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $75.14K | -80.6% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $1.03M | +518.8% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $563.74K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $256.88K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $386.49K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $167.20K | – |
See a number that looks wrong?